CAM
ALXN

Covenant Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Covenant Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,175
Closed -$400K – 140
2021
Q2 		$400K Hold
2,175
– – 0.12% 107
2021
Q1 		$333K Sell
2,175
-1,823
-46% -$282K 0.1% 125
2020
Q4 		$625K Hold
3,998
– – 0.21% 94
2020
Q3 		$457K Hold
3,998
– – 0.15% 98
2020
Q2 		$449K Sell
3,998
-100
-2% -$10.6K 0.1% 105
2020
Q1 		$368K Sell
4,098
-612
-13% -$60.1K 0.11% 110
2019
Q4 		$509K Hold
4,710
– – 0.22% 97
2019
Q3 		$461K Sell
4,710
-188
-4% -$21.2K 0.23% 99
2019
Q2 		$642K Hold
4,898
– – 0.33% 82
2019
Q1 		$662K Sell
4,898
-1,000
-17% -$124K 0.35% 82
2018
Q4 		$820K Hold
5,898
– – 0.41% 72
2018
Q3 		$820K Hold
5,898
– – 0.41% 72
2018
Q2 		$732K Sell
5,898
-14,878
-72% -$1.74M 0.4% 78
2018
Q1 		$2.32M Buy
20,776
+1,156
+6% +$138K 1.34% 21
2017
Q4 		$2.35M Sell
19,620
-669
-3% -$81.5K 1.36% 19
2017
Q3 		$2.85M Sell
20,289
-143
-0.7% -$19.4K 1.74% 10
2017
Q2 		$2.49M Buy
20,432
+2,598
+15% +$302K 1.59% 12
2017
Q1 		$2.16M Buy
17,834
+734
+4% +$94.6K 1.46% 15
2016
Q4 		$2.09M Buy
+17,100
New +$2.09M 1.4% 22

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Covenant Asset Management's ALXN Position: Q3 2021 in Review

Covenant Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,175 shares — an estimated $400K sold.

Covenant Asset Management first reported a position in ALXN in Q4 2016 and held it in 19 quarters. The position peaked at $2.85M in Q3 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Covenant Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Covenant Asset Management sold 2,175 Alexion Pharmaceuticals shares in Q3 2021, an estimated $400K.
  • Covenant Asset Management first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 19 quarters.
  • Covenant Asset Management's Alexion Pharmaceuticals position peaked at $2.85M in Q3 2017.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Covenant Asset Management's 13F filing for Q3 2021, filed 15 Oct 2021.